{"analyses":[{"ciLowerLimit":"-2.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-1.18","groupDescription":"From an ANCOVA model including scores at Baseline, treatment group, region and MRI/CRP classification.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.001","paramType":"Difference","paramValue":"-1.90","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.5","value":"-2.1"},{"groupId":"OG001","spread":"0.4","value":"-4.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"The nocturnal spinal pain experienced by subjects due to AS was measured by following question 'How much pain of your spine due to spondylitis do you have at night?'. The NRS ranged from 0 to 10, where 0 represented 'no pain' and 10 represented 'most severe pain'. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.","dispersionType":"Standard Error","groups":[{"description":"Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards. Subjects formed the Full Analysis Set (FAS).","id":"OG000","title":"Placebo (FAS)"},{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the FAS.","id":"OG001","title":"CZP 200 mg Q2W (FAS)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The FAS consisted of all subjects in the RS who have received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"From Baseline to Week 52","title":"Change From Baseline in Nocturnal Spinal Pain Numerical Rating Scale (NRS) at Week 52","type":"SECONDARY","unitOfMeasure":"scores on a scale"}